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Abstract
Aim: To evaluate the performance of eight different sets
of gentamicin populational pharmacokinetic parame-
ters, regarding potential implementation in clinical
pharmacokinetic software as prior information.
Methods: The study involved 49 patients of
31.3±4.1 weeks of gestational age (GA), receiving
gentamicin, and for whom peak and trough concen-
trations were obtained. Accuracy and precision were
assessed by mean prediction error (ME), mean squared
prediction error (MSE) and root mean squared predic-
tion error (RMSE). Weighted prediction-error analysis
was carried out in order to evaluate peak and trough
concentrations together (MEw, MSEw and RMSEw).
Results: The analysis showed CL=0.036 l/h/kg
(<34 weeks GA) or CL=0.051 l/h/kg (‡34 weeks
GA), andVd=0.5 l/kg (£37 weeks GA) orVd=0.4 l/kg
(>37 weeks of GA) as the most accurate and precise
set of pharmacokinetic parameters (Set 4), presenting
the highest percentage of clinically acceptable estimates
(ErrorPeak<1 lg/ml, and ErrorTrough <0.375 lg/ml).
Conclusion: The adoption of the previously mentioned
set of parameters as population estimates seems to be
the best option, bearing in mind the obtained results.
However, we strongly believe that pharmacokinetic
parameter determination of gentamicin should be car-
ried out whenever possible in order to improve the
rationale and cost-effectiveness of therapy.
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Introduction
Intensive care unit (ICU) patients routinely meet the
criteria outlined by several authors to be included in
therapeutic drug monitoring programmes. Dosage
adjustments based on individual pharmacokinetic
parameters are of considerable importance for effective
and safe use of drugs [1, 2]. This is especially true for
children, for whom the kinetic and dynamic processes
are usually not as well characterised as for the adult
population. Neonates present the additional challenge
of having a set of mechanisms changing with alarming
rapidity on a day-to-day basis [3–5].
In reviewing paediatric literature, there is an obvious
lack of information for most therapeutic agents in
neonates concerning pharmacokinetic and/or pharma-
codynamic data. Furthermore, some of the most often
used drugs in this subpopulation (e.g., antibiotics)
present relatively narrow therapeutic ranges. Gentami-
cin, which is often used in the treatment of suspected or
proven gram-negative infections in this age group, has
been shown to be ototoxic and nephrotoxic in the adult
population. Although gentamicin toxicity in newborns
is not well documented, it may be reasonable to expect
similar or even more pronounced effects in infants [1, 4].
In order to improve gentamicin therapy in Portu-
guese neonates, the Bayesian approach seems to be an
appropriate methodology to optimise the dosage
schedules required to achieve desirable target concen-
trations (peak and trough serum levels).
Aim
The aim of the present work was to evaluate the per-
formance of eight different sets of gentamicin phar-
macokinetic parameters, obtained by different authors,
regarding potential implementation in a clinical phar-
macokinetic program (PKS System; Abbott Labora-
tories, Abbott Park, IL, USA) as prior information.
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Methods
Patients
A retrospective review of pharmacokinetic data of
gentamicin was performed in 49 neonates admitted in
the neonatal intensive care unit at Coimbra University
Hospital (CUH) between 2000 and 2003. All the se-
lected patients had a postnatal age of below one week
and two available gentamicin serum concentrations
(peak and trough) obtained according to routine clin-
ical protocol. The group had the following character-
istics, expressed as mean and standard deviation: birth
weight (1.79±0.80 kg), gestational age (31.3±
4.1 weeks), and serum creatinine (0.96±0.30 mg/dl).
Gentamicin dosing and sampling times
A standard 2.5 mg/kg dose the gentamicin was
administered through a 10-min slow intravenous
infusion and the interval between doses was selected on
the basis of patients’ weight: 24-, 18- and 12-h intervals
for weights <1200, 1200–2000 and >2000 g, respec-
tively.
Two blood samples (1 h after the end of adminis-
tration, and 30 min before the next dose) were rou-
tinely collected after 24 and 48 h starting the therapy.
The assumed target concentrations for gentamicin
were defined to be 0.5–2 and 6–10 lg/ml for trough
and peak levels, respectively [2, 3, 6].
Serum samples were collected via venipuncture and
gentamicin concentrations were determined by a fluo-
rescence polarisation immunoassay technique (TDx;
Abbott Diagnostics) at the Laboratory of Hormono-
logy and Therapeutic Drug Monitoring of CUH. This
assay had a coefficient of variation (CV) lower than
6% in our institution and the sensitivity was 0.27 lg/
ml; these two values were taken into account for sub-
sequent analysis.
Pharmacokinetic analysis
The PKS computer program (Abbott Laboratories,
Abbott Park, IL, USA) was used to evaluate the
prediction of gentamicin concentrations in our pop-
ulation. The kinetic analysis was carried out assuming
a one-compartment open model with zero-order
absorption (short infusion) and first-order elimina-
tion. Since no database concerning gentamicin infor-
mation in a newborn population was available in the
original program package, the populational pharma-
cokinetic parameters used for estimating the predic-
tive performance were those most reported in the
literature. Several sets of gentamicin pharmacokinetic
parameters involving populational estimates for both
gentamicin clearance and volume of distribution were
established according to different authors (Table 1).
Eight Sets were then tested: four (Sets 1–4) were
obtained using traditional methodology (Stand Two-
Stage Method – STS), and the remaining four (Sets
5–8) were determined through an alternative meth-
odology (Populational Approach – PA). These Sets
were used to calculate the predicted concentrations
according to the demographic and clinical character-
istics of the patients, which provided the present work
with the clinical environment for this kind of popu-
lation research.
Predictive performance
The absolute and relative predictive performances were
evaluated applying the Prediction-Error analysis as
suggested by Sheiner & Beal [9] the most used meth-
odology involving comparison of predicted (calculated
by the Sets) and observed (measured) drug concen-
trations. Prediction error was defined as the predicted
minus the observed serum gentamicin concentrations.
The Prediction-Error analysis involved the calculation
of mean prediction error (ME), a measure of accuracy;
mean squared prediction error (MSE), representing
precision; and the root mean squared prediction error
(RMSE), a measure of both accuracy and precision.
Weighted (normalisation of the ME by the observed
concentrations) prediction-error analysis (MEw, MSEw
and RMSEw) was carried out in order to evaluate all
(peak and trough) concentrations together.
The smaller the ME, MSE and RMSE, the less
biased and more precise the results should be. Bias was
tested by comparing the mean prediction error with
zero using the Student’s t-test. Comparison of the
predictive capacity of the different Sets, regarding
accuracy and precision, was done by analysis of vari-
ance (ANOVA). Relative predictive performance was
assessed by the differences in values for ME (DME)
and MSE (DMSE) and their 95% confidence intervals.
If the 95% confidence intervals for the relative per-
formance criteria did not include zero, the predictions
were considered to be significantly different. Paramet-
ric statistical calculations were used because the data
were normally distributed. The significant probability
level chosen was P £ 0.05. Statistica for Windows
(Version 6.1; Statsoft, Inc., Tulsa, OK, USA) was used
to perform all statistical tests.
To assess the practical clinical performance of our
sets, the individual prediction errors were arranged in
two groups for peak and trough concentrations [10]:
errors higher than 1 lg/ml for peak and 0.375 lg/ml
for trough serum levels were considered as unaccept-
able errors. The clinical performance of each set of
parameters was evaluated according to the percentage
of acceptable estimates.
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Results
The predictive performances of the eight Sets were
evaluated by prior prediction for peak and trough
levels. It must be emphasised that all sets presented
negative ME values for both peak and trough levels,
indicating an underprediction of the observed con-
centrations. In the STS group (Sets 1–4), Set 4
exhibited the best accuracy and precision measures
evaluated by ME, MSE, and confirmed by RMSE
values for peak concentrations. This is also true for
trough levels, except for accuracy, for which the
predictive capacity of Sets 3 and 4 appears to be
similar. In the PA group (Sets 5–8), Set 7 showed the
best accuracy and precision measures for peak levels.
Otherwise, concerning trough concentrations, Set 8
appears to be slightly better than Set 7. However,
when the available data (peak and trough levels) were
analysed together using the weighted absolute pre-
dictive capacity (MEw, MSEw and RMSEw), Sets 4
and 7 proved to be the best sets of pharmacokinetic
parameters regarding the predictive performance
(Table 2).
Additionally, Sets 4 and 7 were selected as a refer-
ence in order to evaluate the relative predictive
capacity of Sets in the STS group and PA group,
respectively. All Sets denoted significant differences
when compared with the references for both accuracy
and precision. Furthermore, the comparison between
Sets 4 and 7 revealed Set 4 as the most precise and
accurate set of pharmacokinetic parameters. These
observations were confirmed by the variance analysis
performed to find differences between the Sets.
Finally, the clinical performance of the methods was
evaluated by the percentage of acceptable errors (Er-
rorPeak <1 and ErrorTrough <0.375 lg/ml). Set 4
showed the largest percentage (34%) of clinically
acceptable errors in prior prediction; on the other
hand, Set 8 expressed poor precision and accuracy,
showing the highest percentage (84%) of rejected
estimate concentrations, which is a very high value
considering its potential application in clinical practice.
Table 1 Population pharmacokinetic parameters of gentamicin
Parameters References
CL (l/h/kg) Vd (l/kg)
Set 1 GA 23–27 0.052 0.540 Murphy et al. [3]
GA 28–33 0.043 0.480
GA 34–37 0.047 0.460
GA 38–42 0.047 0.410
Set 2 GA <28 0.041 0.610 Semchuk et al. [6]
GA 28–29 0.045 0.660
GA 30–34 0.048 0.530
GA 34–40 0.081 0.510
Set 3 GA £34 0.043 0.670 Semchuk et al. [4]
GA >34 0.048 0.520
Set 4 GA <34 0.036 0.500 Delgado et al. [2]
GA 34–37 0.051 0.500
GA >37 0.051 0.400
Set 5 Covariates for CL (l/h): WT (kg); GA (weeks); PNA (days); PCA
(weeks)
Izquierdo et al. [7]
Covariate for Vd (l): WT (kg)
Set 6 Covariates for CL (l/h): WT (kg); Age (days); Serum creatinine
(lmol/l)
Kelman et al. [5]
Covariate for Vd (l): WT (kg)
Set 7 Covariates for CL (l/h): WT (kg); PCA (weeks); Apgar Thomson et al. [8]
Covariate for Vd (l): WT (kg)
Set 8 Covariates for CL (l/h): WT (kg); GA (weeks); Serum creatinine
(lmol/l)
Weber et al. [1]
Covariate for Vd (L): WT (kg)
WT, weight; GA, gestational age; PCA, postconceptional; PNA, postnatal age. Sets 1–4: Standard Two-Stage (STS); Sets 5–8:
Population Approach (PA).
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Discussion
The variability in the pharmacodynamic response
following administration of standard doses is due in
part to inter- and intra-individual pharmacokinetic
variability. Furthermore, the effects of drugs on
developmental processes that are on going in preterm
and term neonates cannot be assessed in older children
or adults [2, 3, 7].
Bearing in mind the wide range of values for the
populational pharmacokinetic parameters of genta-
micin presented by the selected bibliographical infor-
mation (Table 1) and the constant evolution of
children, it seemed important to analyse their predic-
tive performance in order to characterise our popula-
tion kinetic profile. In fact, investigations into the
effects on drug disposition in these patients have been
made with the aim of providing improved a priori
predictions of serum concentration time profiles and
thereby dynamic response. Despite these advances in
theory and practice, the accuracy with which drug
dosage regimens and/or the likelihood of drug inter-
actions can be predicted for the individual patient re-
mains problematic [3, 5, 7).
In the present work, from the prediction-error
analysis of the eight sets of pharmacokinetic parame-
ters obtained from the literature, it must be emphas-
ised that all of them presented negative ME values for
both peak and trough levels, indicating a persistent
underprediction of the observed concentrations. This
may be related to the specific characteristics of our
study population, 39% of which consisted of neonates
of 26–28 weeks of gestational age.
In the STS group (Sets 1–4), Method 4 [2] was the
most similar concerning demographic and clinical
characteristics of the studied neonates, which may
explain the acceptable clinical performance showed by
this set of pharmacokinetic parameters regarding
gentamicin concentration predictions. Additionally, it
must be pointed out that the mentioned study was
carried out in Spain, which is the nearest country to
Portugal in terms of geographic, demographic and
cultural aspects. In the PA group (Sets 5–8), Set 7 [8]
appeared to be the best one in terms of predictive
capacity, which can be confirmed by the clinically
acceptable errors in prior prediction. Although Set 5
[7] was carried out with Spanish neonates (as happened
with Set 4), the studied population did not include
patients with low gestational age, which can explain
the relatively poor clinical performance of this set of
pharmacokinetic parameters in comparison with Set 7.
This analysis sustained as an other studies a signifi-
cant portion of the variability in gentamicin pharma-
cokinetics parameters in neonates less 7 days old and,
unlike current step-based approaches, allows the gen-
tamicin dose to reflect the difference in gestational age
within each dosing group [1, 4].T
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Conclusion
The obtained results led us to choose Sets 4 and 7 as
the most reliable sets of parameters for the STS group
and PA group, respectively. Furthermore, a compari-
son between both methods revealed that Set 4
(CL=0.036/0.051 l/h/kg for neonates of gestational
age <34 or ‡34 weeks, respectively; Vd=0.5/0.4 l/kg
for neonates of gestational age £37 or >37 weeks,
respectively) is the most accurate and precise in pre-
dicting gentamicin concentrations. Otherwise, it must
be stressed that the adopted methodology for the
determination of populational pharmacokinetic
parameters (STS versus PA) did not appear to be
decisive for the accuracy and precision of gentamicin
predictions, but caution must be exercised in extrapo-
lating kinetic information to patients in other settings
without previous validation.
As a final remark, despite the acceptable predictive
and clinical performances obtained with Set 4, the
overall results of our study support the idea that
neonate gentamicin pharmacokinetic parameters in
our population should be determined in order to im-
prove the rationale and cost-effectiveness of this anti-
microbial therapy.
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